Document is current

Article History

Received: 5 December 2024

Accepted: 21 February 2025

First Online: 4 August 2025

Acknowledgements

: Medical writing in English and editorial assistance were provided by Festina Lente (Medellin, Colombia) and funded by Novo Nordisk Colombia. The collaboration agreement between the Pontificia Universidad Javeriana and Springer Nature enabled the open access publication. The authors assume full responsibility for the content and conclusions expressed in this manuscript. Novo Nordisk did not influence the content of this publication nor participate in the study design, data collection, analysis, interpretation or review, or in any stage of the publication process.

: The datasets generated or analysed for the current study are available upon reasonable request from the sponsor institution (Hospital Universitario San Ignacio).

: Open Access funding provided by Colombia Consortium. This research was funded by a grant from the Asociación Colombiana de Endocrinología, Diabetes y Metabolismo (ACE).

: AMG-M received speaker fees from Novo Nordisk, Astra Zeneca, Sanofi, Eli Lilly, Boehringer Ingelheim, Abbott and Medtronic. DCH-C received speaker fees from Novo Nordisk, Sanofi and Abbott. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: AMG-M conceived the study. AMG-M, DCH-C, LPV-C, OMM-V, CAY, YG-Q and PA designed the study, analysed the data and critically reviewed the protocol. SNC and CEP-N participated in the acquisition of data and database elaboration. All authors contributed to the final version of the manuscript, and approved the version to be published. AMG-M is the guarantor of this work, and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.